Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
Clin Liver Dis
; 24(4): 719-737, 2020 11.
Article
em En
| MEDLINE
| ID: mdl-33012455
ABSTRACT
Sorafenib was the first tyrosine kinase inhibitor (TKI) that showed success in extending survival in patients with advanced hepatocellular carcinoma (HCC). In recent years, additional TKIs have been shown to improve survival and expanded the armamentarium for treating this malignancy. The current landscape includes other classes of drugs, such as immune checkpoint inhibitors and monoclonal antibodies. The challenge is now placed on how to best select, combine, and sequence drugs with the goal of improving efficacy and minimizing toxicities to deliver better outcomes for HCC patients.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Tirosina Quinases
/
Carcinoma Hepatocelular
/
Inibidores de Proteínas Quinases
/
Neoplasias Hepáticas
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article